EPO Medicare rates
Measure requiring HHS to report to Congress on the "methodology and rationale" used to establish Medicare rates for erythropoietin is included in budget reconciliation legislation passed by Congress on Nov. 22. The study earlier was proposed by House Ways & Means Health Subcommittee Chairman Stark (D-Calif.) ("The Pink Sheet" June 19, T&G-1). As many as 25,000 medicare kidney dialysis patients may use the anti-anemia drug in the first year of coverage, at a cost of $ 5,600 annually per patient. Amgen's Epogen is currently the only approved EPO product.
You may also be interested in...
The president’s executive order aims to give smaller companies a leg up over foreign competitors, among other objectives.
No device-related warning letters were released by the US FDA the week of 26 January.
Karyopharm and GSK should soon learn whether the European Medicines Agency will recommend EU approval for their respective products, selinexor and dostarlimab.